Preclinical assessment of phosphopyricin and analogs as novel phosphine-based antibiotics

磷酸吡啶及其类似物作为新型磷化氢抗生素的临床前评估

• 批准号: 467161
• 负责人: Cullen Alexandra L
• 金额: $ 1.27万
• 依托单位: University of Saskatchewan
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-12-01 至 2022-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=467161&lang=en
• 关键词: Antibiotic; Broad-Spectrum Antibiotic Resistance; Drug Characterization; Methicillin-Resistant Staphylococcus Aureus; Next-Generation Antibiotics; Pharmacokinetics; Preclinical Drug Development; Priority Pathogens; Toxicology; Wound Healing

The threat of antimicrobial resistance is exemplified by the multidrug-resistant (MDR) ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species). These

抗菌素耐药性的威胁以多药耐药（MDR）ESKAPE病原体（屎肠球菌、金黄色葡萄球菌、肺炎克雷伯菌、鲍曼不动杆菌、铜绿假单胞菌和肠杆菌属）为例。这些